Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Shiwei Guo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1020-0236; OpenAlex author ID A5102983703. Sources: OpenAlex.

Their work

Papers
46 (first author 12, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
120
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 4 papers · 2020: 4 papers · 2021: 6 papers · 2022: 5 papers · 2023: 9 papers · 2024: 3 papers · 2025: 8 papers · 2026: 3 papers

Papers 46

  1. Prognostic value of multiparameter [68Ga]Ga-DOTA-FAPI-04 PET/MR imaging biomarkers for patients with advanced pancreatic cancer. First author DOI 10.1007/s00259-025-07491-w↗
  2. ARNTL2 promotes metastatic phenotypes through SERPINE1 transcription in KRAS G12D pancreatic cancer. Co-author DOI 10.1016/j.isci.2026.117479↗
  3. T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial. Co-author DOI 10.1016/j.ymthe.2026.03.012↗
  4. Preoperative assessment of pancreatic cancer with [68Ga]Ga-DOTA-FAPI-04 PET/MR versus [18F]-FDG PET/CT plus contrast-enhanced CT: a prospective preliminary stu… First author DOI 10.1007/s00259-024-06943-z↗
  5. A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapy. Co-author DOI 10.1016/j.stem.2025.07.008↗
  6. Periarterial divestment following neoadjuvant therapy in patients with locally advanced pancreatic cancer with celiac axis invasion: A safe and effective surgi… Co-author DOI 10.1016/j.surg.2024.109045↗
  7. A practical distribution pattern of α-SMA-positive carcinoma associated fibroblasts indicates poor prognosis of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2025.102282↗
  8. Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients. Co-author DOI 10.1038/s41467-025-57520-3↗
  9. Cell-free DNA testing for the detection and prognosis prediction of pancreatic cancer. Co-author DOI 10.1038/s41467-025-61890-z↗
  10. Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. First author DOI 10.1172/jci.insight.181873↗
  11. Senescence-driven molecular subtyping in pancreatic cancer: a multi-omics framework for precision medicine. Co-author DOI 10.1186/s12885-025-15341-z↗
  12. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-023-02790-x↗
  13. Functional characteristics of DNA N6-methyladenine modification based on long-read sequencing in pancreatic cancer. First author DOI 10.1093/bfgp/elad021↗
  14. Integrated 68 Ga-FAPI-04 PET/MR in Pancreatic Cancer : Prediction of Tumor Response and Tumor Resectability After Neoadjuvant Therapy. First author DOI 10.1097/rlu.0000000000005300↗
  15. Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101162↗
  16. Morphomolecular staging to improve stratification of patients with node-negative pancreatic cancer. Co-author DOI 10.1093/bjs/znac457↗
  17. A novel staging system derived from natural language processing of pathology reports to predict prognostic outcomes of pancreatic cancer: a retrospective cohor… Co-author DOI 10.1097/js9.0000000000000648↗
  18. A Case of Pancreatic Cancer With Rare Cutaneous and Muscle Metastases on 18 F-FDG PET/CT Imaging. First author DOI 10.1097/rlu.0000000000004699↗
  19. A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-023-11181-x↗
  20. Combined utility of Ki-67 index and tumor grade to stratify patients with pancreatic ductal adenocarcinoma who underwent upfront surgery. Co-author DOI 10.1186/s12893-023-02256-4↗
  21. Systemic Immune-Inflammation Index After Neoadjuvant Therapy Predicts the Pathological Response in Patients with Resected Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-2856912/v1↗
  22. Genome-wide identification of A-to-I RNA editing events provides the functional implications in PDAC. Co-author DOI 10.3389/fonc.2023.1092046↗
  23. [Establishment of the quality assessment system for pancreatic cancer surgery: from "single complication assessment" to "textbook outcome"]. First author DOI 10.3760/cma.j.cn112139-20230308-00097↗
  24. Systemic therapy and perioperative management improve the prognosis of pancreatic ductal adenocarcinoma: A retrospective cohort study of 2000 consecutive cases. Co-author DOI 10.1016/j.ijsu.2022.106786↗
  25. Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity. Co-author DOI 10.1038/s41467-022-29857-6↗
  26. Negative p53 Expression Confers Worse Prognosis in Patients With Resected Pancreatic Ductal Adenocarcinoma: Research Focused on Reinterpretation of Immunohisto… Last author DOI 10.1097/mpa.0000000000002175↗
  27. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA. First author DOI 10.1186/s12916-022-02647-z↗
  28. Radiomics nomogram for the preoperative prediction of lymph node metastasis in pancreatic ductal adenocarcinoma. First author DOI 10.1186/s40644-021-00443-1↗
  29. Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Co-author DOI 10.1002/ctm2.520↗
  30. Tumor microbiome contributes to an aggressive phenotype in the basal-like subtype of pancreatic cancer. Co-author DOI 10.1038/s42003-021-02557-5↗
  31. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08380-9↗
  32. Which Factors Are Associated with Positive Resection Margin in Pancreatic Ductal Adenocarcinoma for different surgical procedures? Results Based on a Standard … First author DOI 10.21203/rs.3.rs-111309/v2↗
  33. The Landscape of Microbial Composition and Associated Factors in Pancreatic Ductal Adenocarcinoma Using RNA-Seq Data. Last author DOI 10.3389/fonc.2021.651350↗
  34. The Landscape of Genetic Alterations Stratified Prognosis in Oriental Pancreatic Cancer Patients. Co-author DOI 10.3389/fonc.2021.717989↗
  35. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for… Co-author DOI 10.1016/j.surg.2020.02.013↗
  36. Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients. Co-author DOI 10.1038/s41416-019-0704-2↗
  37. Radical antegrade modular pancreatosplenectomy versus standard distal pancreatosplenectomy for pancreatic cancer, a dual-institutional analysis. First author DOI 10.21037/cco-20-6↗
  38. Pros and Cons: High Proportion of Stromal Component Indicates Better Prognosis in Patients With Pancreatic Ductal Adenocarcinoma-A Research Based on the Evalua… Co-author DOI 10.3389/fonc.2020.01472↗
  39. Menin Coordinates C/EBPβ-Mediated TGF-β Signaling for Epithelial-Mesenchymal Transition and Growth Inhibition in Pancreatic Cancer. Co-author DOI 10.1016/j.omtn.2019.08.013↗
  40. Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer. Co-author DOI 10.1096/fj.201800617r↗
  41. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: stu… Co-author DOI 10.1186/s13014-019-1254-8↗
  42. [Prognostic value of important driver gene mutations in patients with radical resection of pancreatic cancer]. Co-author DOI 10.3760/cma.j.issn.0529-5815.2019.11.009↗
  43. Identification and functional analysis of heterogeneous FOXP3+ Treg cell subpopulations in human pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.scib.2018.05.028↗
  44. CD13hi Neutrophil-like myeloid-derived suppressor cells exert immune suppression through Arginase 1 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2016.1258504↗
  45. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients. Co-author DOI 10.1002/ijc.28471↗
  46. miR-545 inhibited pancreatic ductal adenocarcinoma growth by targeting RIG-I. Co-author DOI 10.1016/j.febslet.2014.10.004↗

Closest collaborators

The 25 strongest of 120 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gang Jin · 33 shared papers, 2014–2026 · strength 4.74
  2. Suizhi Gao · 25 shared papers, 2019–2026 · strength 3.57
  3. Xiaohan Shi · 24 shared papers, 2019–2026 · strength 3.43
  4. Kailian Zheng · 15 shared papers, 2019–2026 · strength 2.43
  5. Xiaoyi Yin · 13 shared papers, 2021–2026 · strength 2.21
  6. Xiongfei Xu · 12 shared papers, 2017–2026 · strength 1.78
  7. Guoxiao Zhang · 10 shared papers, 2021–2025 · strength 1.52
  8. Bo Li · 10 shared papers, 2020–2023 · strength 1.33
  9. Lingyu Zhu · 6 shared papers, 2023–2025 · strength 1.16
  10. Gang Jin · 5 shared papers, 2022–2026 · strength 1.08
  11. Chao Cheng · 4 shared papers, 2023–2026 · strength 1.01
  12. Shuo Shen · 8 shared papers, 2019–2023 · strength 1.01
  13. Yunguang Li · 5 shared papers, 2022–2025 · strength 0.80
  14. Dong Gao · 5 shared papers, 2022–2025 · strength 0.80
  15. Zeyu Zhang · 3 shared papers, 2023–2026 · strength 0.77
  16. Meilong Shi · 4 shared papers, 2025 · strength 0.77
  17. Bin Song · 6 shared papers, 2014–2025 · strength 0.76
  18. Changjing Zuo · 3 shared papers, 2024–2026 · strength 0.75
  19. Gang Li · 5 shared papers, 2020–2025 · strength 0.60
  20. Zhuo Shao · 5 shared papers, 2019–2023 · strength 0.52
  21. Gang Y Jin · 4 shared papers, 2017–2025 · strength 0.52
  22. Weiwei Su · 2 shared papers, 2025–2026 · strength 0.51
  23. Hui Jiang · 4 shared papers, 2019–2023 · strength 0.50
  24. Kai Cao · 3 shared papers, 2019–2024 · strength 0.47
  25. Yehan Zhang · 3 shared papers, 2022–2025 · strength 0.45

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.